TherapeuticsMD (NASDAQ:TXMD) +6.1% PM, believes that the company is on track to meet or exceed Q3 total net revenue consensus of $15.1M.
For the ANNOVERA product, orders to wholesalers, retail pharmacies and online distributors across Q3 have increased that are greater than the patient demand numbers being reported by industry prescription tracking databases.
